Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MOTRIN MIGRAINE PAIN vs JUNIOR STRENGTH MOTRIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Reversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin synthesis, thereby alleviating pain and inflammation.
Cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
Migraine headache pain relief (OTC),Primary dysmenorrhea,Rheumatoid arthritis,Osteoarthritis,Mild to moderate pain,Fever reduction
FDA-approved for relief of mild to moderate pain,fever reduction,off-label uses include migraine and dysmenorrhea
Ibuprofen 400 mg orally every 4-6 hours as needed, maximum 1200 mg in 24 hours.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription.
2 hours (1.5-2.5 h in adults; prolonged in elderly and renal impairment).
1.5-2 hours in children; prolonged in neonates (up to 30 hours) and renal impairment. Clinical: short half-life requires frequent dosing for sustained antipyresis/analgesia.
Primarily hepatic via CYP2C9; metabolites undergo glucuronidation and renal excretion.
Primarily hepatic via CYP2C9, with minor contributions from CYP2C8 and glucuronidation.
Renal: 90% (metabolites and unchanged, 10-20% unchanged). Biliary/Fecal: <5%.
Renal excretion of inactive metabolites and conjugates (>90%); less than 10% excreted unchanged. Fecal elimination minor (<5%).
99% bound to albumin.
99% bound to albumin.
0.1-0.2 L/kg. Clinical meaning: Low Vd indicates limited tissue distribution, primarily in plasma.
0.2 L/kg in children; low Vd indicates limited tissue distribution and high plasma protein binding. Clinical: mainly confined to vascular compartment.
Oral: 80-100% (absolute bioavailability).
Oral: 80-100% (rapid absorption); rectal: approximately 70-80%.
e GFR 30-59 m L/min: No adjustment; e GFR 15-29 m L/min: Reduce dose to 200 mg every 6-8 hours, maximum 600 mg/day; e GFR <15 m L/min: Avoid use.
GFR 30-59 m L/min: reduce dose by 50% or avoid; GFR <30 m L/min: contraindicated.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Use with caution, reduce dose by 50%; Child-Pugh Class C: Avoid use.
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: avoid use.
Children weighing ≥50 kg: Same as adult; <50 kg: 7.5-10 mg/kg per dose every 6-8 hours, maximum 30 mg/kg/day.
6 months to 12 years: 5-10 mg/kg per dose orally every 6-8 hours; maximum 40 mg/kg/day.
Start at lowest effective dose (200 mg every 6-8 hours), monitor renal function and gastrointestinal bleeding risk; maximum 600 mg/day.
Initiate at lowest effective dose; consider renal function; increase dosing interval to every 6-8 hours.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time without warning symptoms. Elderly patients and those with a prior history of peptic ulcer disease or GI bleeding are at greater risk.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. NSAIDs are contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
Increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke; risk of serious GI adverse events; avoid in setting of coronary artery bypass graft (CABG) surgery; renal toxicity; anaphylactoid reactions; severe skin reactions (e.g., Stevens-Johnson syndrome); may blunt the antihypertensive effect of ACE inhibitors; avoid late pregnancy due to risk of premature closure of ductus arteriosus.
Risk of GI ulceration, bleeding, and perforation; increased cardiovascular thrombotic events; hypertension; fluid retention and edema; severe skin reactions (e.g., Stevens-Johnson syndrome); renal toxicity, especially in patients with impaired renal function; anaphylactoid reactions.
Known hypersensitivity to ibuprofen or any component of the formulation; history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; perioperative pain in the setting of coronary artery bypass graft (CABG) surgery; late pregnancy (third trimester).
Hypersensitivity to ibuprofen or any NSAID; history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; perioperative pain in CABG surgery; severe renal impairment; history of GI bleeding or perforation related to NSAIDs.
Avoid alcohol and caffeine-containing foods/drinks (coffee, tea, cola, chocolate) due to additive caffeine effects. Grapefruit juice may increase ibuprofen absorption; consider avoidance. No other significant dietary restrictions.
Take with food or milk to minimize gastrointestinal irritation. Avoid alcohol while taking this medication as it increases risk of stomach bleeding.
First trimester: Risk of spontaneous abortion and congenital malformations (cardiac, gastroschisis). Second trimester: Avoid due to possible oligohydramnios and fetal renal impairment. Third trimester: Contraindicated after 30 weeks gestation due to risk of premature closure of ductus arteriosus and persistent pulmonary hypertension. NSAID use after 20 weeks may cause oligohydramnios from fetal renal dysfunction.
First trimester: Increased risk of miscarriage and congenital malformations (cardiac, gastroschisis) with NSAID use; a causal relationship has not been firmly established. Second trimester: Generally considered lower risk, but avoid prolonged use. Third trimester: Known association with premature closure of the ductus arteriosus, oligohydramnios, and fetal renal dysfunction; contraindicated after 30 weeks gestation.
Ibuprofen is excreted into breast milk in low amounts (M/P ratio approximately 0.6-1.0). Peak infant dose is less than 1% of maternal weight-adjusted dose. Considered compatible with breastfeeding; use lowest effective dose for shortest duration.
Ibuprofen is excreted into breast milk in very low amounts (M/P ratio approximately 0.01-0.02). Peak milk concentration occurs 1-2 hours after maternal dose. Due to the low concentration and short half-life in infants, ibuprofen is considered compatible with breastfeeding when used at recommended doses for short durations.
No standard pharmacokinetic data mandating dose adjustment in pregnancy. However, increased renal clearance and volume of distribution may require higher doses for efficacy; use lowest effective dose and avoid third trimester. No specific dosage adjustment recommended in product labeling.
No specific dose adjustment is recommended in pregnancy for occasional use. However, due to pharmacokinetic changes (increased volume of distribution and clearance), lower doses may be less effective; use the lowest effective dose for the shortest duration. Avoid routine use after 20 weeks due to fetal risks.
Motrin Migraine Pain contains ibuprofen 200 mg and caffeine 65 mg per tablet. Caffeine enhances analgesic effect and may help with migraine-associated fatigue. Absorb more rapidly on empty stomach; take at first sign of migraine. Avoid in patients with aspirin allergy, peptic ulcer disease, or uncontrolled hypertension.
For pediatric patients, use weight-based dosing (5-10 mg/kg/dose) rather than age-based to ensure efficacy and safety. Limit to 4 doses per day; maximum 40 mg/kg/day or 1.2 g/day, whichever is less. Do not combine with other NSAIDs. Use lowest effective dose for shortest duration. Contraindicated in children with active peptic ulcer disease, severe renal impairment, or known hypersensitivity to ibuprofen or aspirin.
Take with food or milk if stomach upset occurs.,Do not exceed 2 tablets in 24 hours unless directed by a doctor.,Avoid other caffeine-containing products while taking this medication.,Seek medical attention if migraine is severe or accompanied by stiff neck, speech changes, or vision loss.,Do not use for more than 10 days for headache or 3 days for fever.,Discontinue and contact doctor if rash, swelling, or breathing difficulty occurs.
Give with food or milk to reduce stomach upset.,Use weight-based dosing: shake suspension well before use; use dosing syringe or cup provided.,Do not exceed 4 doses in 24 hours; wait at least 4 hours between doses.,Do not give with other pain relievers containing ibuprofen, naproxen, or aspirin.,Stop use and consult doctor if pain worsens or lasts more than 10 days, or if fever lasts more than 3 days.,Seek medical help immediately if signs of allergic reaction (rash, hives, swelling, trouble breathing) or stomach bleeding (bloody or black stools, vomit that looks like coffee grounds) occur.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MOTRIN MIGRAINE PAIN vs JUNIOR STRENGTH MOTRIN, answered by our medical review team.
MOTRIN MIGRAINE PAIN is a NSAID Analgesic that works by Reversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin synthesis, thereby alleviating pain and inflammation.. JUNIOR STRENGTH MOTRIN is a NSAID Analgesic that works by Cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MOTRIN MIGRAINE PAIN and JUNIOR STRENGTH MOTRIN depend on the specific clinical indication. These are both NSAID Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MOTRIN MIGRAINE PAIN is: Ibuprofen 400 mg orally every 4-6 hours as needed, maximum 1200 mg in 24 hours.. The standard adult dose of JUNIOR STRENGTH MOTRIN is: 200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MOTRIN MIGRAINE PAIN and JUNIOR STRENGTH MOTRIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MOTRIN MIGRAINE PAIN is classified as Category C. First trimester: Risk of spontaneous abortion and congenital malformations (cardiac, gastroschisis). Second trimester: Avoid due to possible oligohydramnios and fetal renal impairm. JUNIOR STRENGTH MOTRIN is classified as Category C. First trimester: Increased risk of miscarriage and congenital malformations (cardiac, gastroschisis) with NSAID use; a causal relationship has not been firmly established. Second t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.